Ibrutinib Treatment In Waldenström Macroglobulinemia Waldenström macroglobulinemia (WM) is a rare type of non-hogdkins lymphoma driven by the gene mutation MYD88L265P. Ibrutinib, the first approved treatment, is effective but can cause side effects. A study found that 27% of WM patients needed to reduce Ibrutinib doses due to side effects like
Eosinophilic Dermatosis In Malignancy (EDHM): Case Study Reports Overview Patients with hematological malignancies may develop various skin eruptions, and one such condition is eosinophilic dermatosis of hematological malignancy (EDHM), also known as an 'insect bite-like' reaction. While cutaneous reactions are not uncommon in hematological malignancies, EDHM is a relatively rare condition that
Acute Myeloid Leukemia And Diverse Patient Survival Outcomes Background Cancer remains a prominent global health concern, accounting for a significant number of cases and fatalities worldwide in 2020, with projections indicating further increases in both incidence and mortality rates, particularly in the United States. Hematologic malignancies (HMs) constitute a substantial subset of
Sinonasal B‐cell lymphomas: A Cohort Study on Progression and Recurrence STUDY BACKGROUND Sinonasal lymphoma is a rare malignancy of rhinologic origin affecting the sinonasal region and surrounding structures. It is a type of non-Hodgkin lymphoma (NHL) comprising around 1.5% of all lymphomas and usually involves males aged between 40 and 70 years.